We read with interest the article by Mehta PA et al. 1 in Leukemia (2006) . Although approximately 30% mutations in perforin gene are associated with familial hemophagocytic lymphohistiocytosis (HLH), the perforin A91V substitution has been shown to result only in a reduced natural killer cell and cytotoxic T lymphocytes cytotoxicity. 2 However, recently some reports have linked perforin A91V substitution to confer increased susceptibility to childhood acute lymphoblastic leukemia 3 (ALL) and lymphoma. 4 But Mehta PA et al. 1 could not substantiate this, in a large cohort of B-precursor childhood ALL. This prompted us to study perforin A91V in our population of childhood ALL and lymphoma patients.
The study population included 52 children with de novo childhood ALL, (Pediatric Oncology Group Classification) enrolled at our center over the past 5 years and nine patients with Non-Hodgkin's Lymphoma (NHL). Concurrently, 100 normal voluntary blood donors were also selected to determine the genotype frequencies from the same ethnic population to be used as controls. Genomic DNA was isolated from peripheral blood lymphocytes and the exons 2 and 3 of the perforin (PRF1) coding region was amplified using standard polymerase chain reaction (PCR). PCR products were then purified and sequenced in ABI 3100 DNA sequencer (Applied Biosystems, Foster City, CA, USA).
Surprisingly, we could not find a single patient (ALL or NHL) or control subject with A91V substitution in this ethnic population from the Sultanate of Oman. A review of literature for population frequencies of perforin A91V revealed an allele frequency ranging between 3 and 17% 1, 5 in Caucasian and 0.7% in Afro-American subjects. 1 Over the past 5 years, we have diagnosed (n ¼ 23 cases) and published several cases with HLH, 6 -8 yet none of our HLH patients nor their immediate family members could be shown to have A91V substitution. Thus, it seems that this ethnic population with distinct links to sub-Saharan eastern African states like Zanzibar does not show the perforin A91V substitution.
Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience Given the therapeutic progress achieved over the last few decades, any improvement in the outcome for the majority of patients with acute lymphoblastic leukemia (ALL) is difficult to assess with the size of the trials. Furthermore, the progress in genetics and molecular biology have now led to the identification of subgroups of patients, typically with poor prognosis markers, for whom intensive treatments were rapidly necessary. For both these clinical aspects, there is an increasing need for intergroup cooperation. We suggest here that multicentric molecular studies could be made more feasible, with scientific rigor, by adopting a common methodological strategy to provide results readily available for therapeutic stratification.
From 1994 to 2000, 984 adults (sex ratio M/F ¼ 1.77) patients aged from 15 to 55 years (median age: 33 years) with newly diagnosed ALL (except patients with a previous history of malignant disease) were enrolled in the LALA-94 trial in 50 clinical centers from four countries (France, Belgium, Switzerland and Australia). The study was approved by the Ethics 
